Identification of the Clinical Development Candidate

Autor: Jay B, Fell, John P, Fischer, Brian R, Baer, James F, Blake, Karyn, Bouhana, David M, Briere, Karin D, Brown, Laurence E, Burgess, Aaron C, Burns, Michael R, Burkard, Harrah, Chiang, Mark J, Chicarelli, Adam W, Cook, John J, Gaudino, Jill, Hallin, Lauren, Hanson, Dylan P, Hartley, Erik J, Hicken, Gary P, Hingorani, Ronald J, Hinklin, Macedonio J, Mejia, Peter, Olson, Jennifer N, Otten, Susan P, Rhodes, Martha E, Rodriguez, Pavel, Savechenkov, Darin J, Smith, Niranjan, Sudhakar, Francis X, Sullivan, Tony P, Tang, Guy P, Vigers, Lance, Wollenberg, James G, Christensen, Matthew A, Marx
Rok vydání: 2020
Předmět:
Zdroj: Journal of medicinal chemistry. 63(13)
ISSN: 1520-4804
Popis: Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target's resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRAS
Databáze: OpenAIRE